AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04121611
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose
Trial: NCT02078856
Drug: A3384
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02055638
Drug: SRX246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT02055638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02527772
Drug: Liposomal Doxorubicin+Gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
Trial: NCT02527772
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Trial: NCT01070225
Drug: Hydrocortisone/ Placebo and Propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 400mcg Propranolol 10mg or 20 mg
Trial: NCT01245569
Drug: Foster® 100/6 µg/unit dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
Trial: NCT01245569
Drug: Seretide Accuhaler® 500/50 µg/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
Trial: NCT01115322
Drug: Vehicle Foam without irradiation
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT01117454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, similar in appearance to flecainide
Trial: NCT01117454
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
Trial: NCT01115322
Drug: Vehicle Foam with UVA and UVB irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT01115322
Drug: Vehicle Foam with UVA and UVB and visible light irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT01115322
Drug: No Treatment without irradiation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT01115322
Drug: No Treatment with UVA and UVB irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT01115322
Drug: No Treatment with UVA and UVB and visible light irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Trial: NCT00824733
Drug: PF03512676
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
Trial: NCT01555242
Drug: Aneustat (OMN54)
RxNorm normalized name: Laminaria angustata extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
Trial: NCT00523445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
Trial: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - low
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - medium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264145
Drug: Ethanolic Solution From HFA134a-MDI - high
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264145
Drug: Ethanolic Solution From Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02414529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03221036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-placebo IV infusion
Trial: NCT03900325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00024271
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01855607
Drug: placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
Trial: NCT01736527
Drug: LE Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drop of LE Gel 0.5% administered to the study eye on visit 2
Trial: NCT00483756
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
Trial: NCT00483756
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Trial: NCT03538171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT00698009
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
Trial: NCT04625907
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
Trial: NCT04625907
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
Trial: NCT03144115
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01495104
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses
Trial: NCT03245359
Drug: Long-term ON-Q
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125%
Trial: NCT01607398
Drug: ADOAIR250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg inhalation, twice daily, from week0 -12.
Trial: NCT01607398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation, twice daily, from week0 -12.
Trial: NCT03478436
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 40 mg capsules
Trial: NCT00138801
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00889616
Drug: BSAM2/Alhydrogel + CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03417401
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
Trial: NCT00326625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03901339
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally per NCCN guidelines
Trial: NCT01092676
Drug: Ibuprofen Regular Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dosing
Trial: NCT01092676
Drug: PRN dosing Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PRN dosing Ibupofen
Trial: NCT00879762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
Trial: NCT02753088
Drug: Copaxone-Teva
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02753088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01007591
Drug: LEO 80190
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied once daily
Trial: NCT01007591
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied once daily
Trial: NCT01810575
Drug: WC3036-13P/Vehicle Only 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cream vehicle 0.5%.
Trial: NCT00474370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of placebo once daily.
Trial: NCT03407300
Drug: Chinese traditional medicine XH1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
Trial: NCT04083235
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
Trial: NCT02780115
Drug: AGN-199201 ophthalmic solution
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Trial: NCT02780115
Drug: AGN-190584 ophthalmic solution
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
Trial: NCT02780115
Drug: AGN-199201 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle to AGN-199201
Trial: NCT02780115
Drug: AGN-190584 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle to AGN-190584
Trial: NCT04083235
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
Trial: NCT02296671
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02296671
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00258310
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/day for one year
Trial: NCT00194116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
Trial: NCT00566384
Drug: Dehydroepiandrosterone, BAY86-5314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
Trial: NCT00566384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
Trial: NCT02208934
Drug: PBF-999
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5, 10, 20 and 40 mg of PBF-999
Trial: NCT02208934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for all dosis of PBF-999
Trial: NCT02269189
Drug: BIIL 284 BS, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269189
Drug: BIIL 284 BS, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03741816
Drug: Indirect pulp capping
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
Trial: NCT01073501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
Trial: NCT03184402
Drug: DWJ1252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184402
Drug: Placebo of Gasmotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184402
Drug: Placebo of DWJ1252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02814500
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT04511975
Drug: IBI188
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI188: 100 mg/mL, intravenous infusion once a week
Trial: NCT03724292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo administered as oral capsule(s) once daily
Trial: NCT03995251
Drug: Testosterone Supplementation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
Trial: NCT03995251
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Treatment
Trial: NCT01916291
Drug: Propess insertion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02438358
Drug: LUM015
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02549339
Drug: LEO 43204 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02549339
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01964755
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Trial: NCT01964755
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate administered starting on Day 2, per study protocol.
Trial: NCT01964755
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
Trial: NCT01209104
Drug: GSK1325756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
Trial: NCT04605991
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01268280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in capsules administered as a single oral dose.
Trial: NCT00575341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral, once daily
Trial: NCT04120701
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
Trial: NCT00565929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline (0.9%).
Trial: NCT03851172
Drug: Ketorolac Ophthalmic
RxNorm normalized name: ketorolac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative administration of Ketorolac 0.5% eye drops
Trial: NCT03851172
Drug: Nepafenac Ophthalmic
RxNorm normalized name: nepafenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative administration of Nepafenac 1 mg eye drops
Trial: NCT02091388
Drug: LY03004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02091388
Drug: Risperdal® Consta®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01410565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Double Blind Phase
Trial: NCT03310333
Drug: Propess® (dinoprostone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis.
Trial: NCT00168766
Drug: Interferon-beta-1a (Avonex) plus methylprednisolone
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration given on 3 consecutive days, monthly as described in protocol.
Trial: NCT02815722
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Trial: NCT02815722
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.